In a declaration, official organizations recommended the indiscriminate use of the traffic light, a medicine used to treat obesity
Whether it’s a trendy diet or a miraculous remedy, if the promise is rapid and effective weight loss, the product will surely become success. This is what happened in Semaglutado, a medicine used in the treatment of obesity and marketed as Ozepica. However, its indiscriminate use can bring various risks, from physical social problems.
In a joint note, the Brazilian Association for the study of obesity (Abeso) and the Brazilian society of endocrinology and metabology (Sbem) intended for the population and guidelines for printing on the use of the drug.
Before then, it is noteworthy that obesity is a chronic, complex, multienic and difficult treatment, as the note points out. “The indication of a pharmacological treatment should be performed by a qualified doctor, taking into account the indications, contraindications, tolerability and patient expectations, not based only on the IMC, but on a wide range of aspects that should be treated consultation. No drug should be used without a prescription and follow, “says the text.
Is this treatment really necessary?
For those who wish to lose weight, it is important to ask yourself before any attitude if the treatment with semaglutado is really necessary. According to Abeso and Sbem, many news confuses what is the serious treatment of obesity with the “social desire to lose weight”.
“Short -term use of aesthetic drugs (and often without prescription) should be treated in a very different way than the serious treatment of obesity, which aims to improve the health and quality of life”, says another extract of the note .
According to the statement, it is also important to move away from the idea that drugs are an “easy way”. This is because it is intended for specific cases, in which a treatment with medicines is even necessary.
Semaglutado
The traffic semaglutid is a drug approved for obesity in different countries of the world at a dose of 2.4 mg per week. In Brazil, the drug received approval on January 2, 2023. However, the 2.4 mg dose is not yet available for sale. So far, only the formulation approved for type 2 diabetes, with a maximum dose of 1.0 mg is available in the country.
Although the use of a dose of 1.0 mg would be “off-label”, the active ingredient is currently approved for obesity. In fact, its high efficiency in the fight against obesity and its good safety profile explains the high demand and interest in drugs. But, unfortunately, the high cost of the traffic light prevents the use by most of our population, which does not have access to medicines for obesity by the unified health system, highlights Sbem and Abeso Note.
Although the patient has access to trafficlutida, his marketing needs a medical prescription, following the standard protocols of Anvisa. “Obesity drugs approved by Anvisa have demonstrated its effectiveness and safety and should not be convicted, but individually selected within a medical consultation and be sold exclusively under prescription. Tolerability and safety,” says the declaration.
The note also underlines that the improper, aesthetic or inadequate use of anobesity drugs, in addition to exposing people at risk without indication of use, increases the stigma of the treatment of those who already suffer from various prejudices in our society. “The questions that worsen this stigma can lead people to abandon successful treatments or avoid looking for medical assistance,” says the text.
Source: joint note from the Brazilian association for the study of obesity (Abeso) e
Brazilian society of endocrinology and metabology (Sbem).
Source: Terra
Ben Stock is a lifestyle journalist and author at Gossipify. He writes about topics such as health, wellness, travel, food and home decor. He provides practical advice and inspiration to improve well-being, keeps readers up to date with latest lifestyle news and trends, known for his engaging writing style, in-depth analysis and unique perspectives.
